Prophylactic CD45RA-depleted DLI After Haploidentical Transplantation/RIC

Status Not yet recruiting

Clinical Trial Summary

To assess safety of prophylactic escaladed dose of T naïve depleted (CD45RA depleted donor lymphocyte infusion, in patients with malignant hemopathie who received an allogeneic stem cell transplant from an haplo-identical donor, after a reduced intensity conditionning regiment.

Clinical Trial Description

Primary Objective is to determine whether the administration of prophylactic CD45RAneg (CD45RAneg) memory/effector T lymphocytes is feasible and safe in the early post-transplant period for patients with haploidentical transplant and RIC conditioning. Donor lymphocytes are isolated from the original donor by non-mobilized mononuclear cell leukapheresis. Repetitive intravenous infusions (up to 3) of escalating doses of CD45RAneg cells, prepared from the leukapheresis by CliniMACS® technology (CD45RA-depletion), storage in vapor nitrogen. Escalating doses of CD45RAneg cells, for patients with haploidentical graft, intervals of 6-8 weeks, if GvHD is absent starting ≥ 4 weeks from the day of transplantation. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05066412
Study type	Interventional
Source	University Hospital, Geneva
Contact
Status	Not yet recruiting
Phase	Phase 1
Start date	October 15, 2021
Completion date	December 2, 2026

View Details

See also
Status	Clinical Trial	Phase
Suspended	`NCT05400122` - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer	Phase 1
Recruiting	`NCT04889937` - Usability, Adherence and Diagnostic Performance of PointCheck in Pediatric Population
Not yet recruiting	`NCT05820126` - Cold Versus Room Temperature Storage of Platelets for Bleeding in Hematologic Malignancy - a Pilot Trial	Phase 2
Active, not recruiting	`NCT04509765` - A Phase II Single-arm Study of Total Body Irradiation With Linac Based VMAT and IGRT	N/A
Not yet recruiting	`NCT06350994` - Early Assessment of Cardiac Function After Treatment With CAR-T Cells
Not yet recruiting	`NCT05443854` - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)	Phase 3
Withdrawn	`NCT04282174` - CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies	Phase 2
Withdrawn	`NCT03986086` - MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation	Phase 1/Phase 2
Completed	`NCT02512666` - Non Invasive Optical Imaging of WBC Count	N/A
Withdrawn	`NCT02207764` - Reiki as a Complementary Therapy: A Pilot Study	N/A
Not yet recruiting	`NCT02193399` - Physiotherapy in Hematopoietic Stem Cell Transplantation	N/A
Terminated	`NCT01846429` - Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain	Phase 1
Terminated	`NCT01215981` - Influenza Vaccine Post Allogeneic Transplant	N/A
Completed	`NCT00333190` - CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation	N/A
Withdrawn	`NCT04392128` - Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE)	Phase 2
Recruiting	`NCT06102213` - Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation	Phase 2
Active, not recruiting	`NCT04552288` - Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies	Phase 2
Completed	`NCT03654404` - A Proof-of-Concept Trial of a Positive Psychology Intervention for Allogeneic Stem Cell Transplant Patients	N/A
Recruiting	`NCT05384288` - Response to Influenza Vaccination in Pediatric Oncology Patients
Recruiting	`NCT05084027` - Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT	Phase 2